Clinical Trial Update: A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of HH2710 in patients with melanoma and other advanced tumors was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Erdheim-chester Disease
• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• HH2710

Snippet

Sponsor: Haihe Biopharma Co., Ltd. | Conditions: Advanced Tumors, Melanoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-07-19